Projects

The OriON JA aims to support the Cancer Inequalities Registry identify trends, disparities and inequalities in cancer prevention and care, both between and within European Member States and regions. This will help target investment and lead to a reduction in measurable disparities across the EU.

The Regulation on Health Technology Assessments significantly increased the role of patient experts in the HTA process so they can provide input on their experience and needs. EUCAPA will improve patient advocate’s skills and knowledge whilst also helping patient organisations to respond to requests

Cancer is a major challenge for Europe. TRANSITION focuses on digital skills training to increase professionals’ digital literacy, usage of digital tools, and effective integration of technology in practice.

The EU is pioneering a brand-new approach to inter-specialty cancer training via the INTERACT-EUROPE 100 programme. Underpinning structures for high performance multi-disciplinary team working in cancer care, the programme offers a comprehensive curriculum of learning that will be implemented in 100

DigiCanTrain implements a new digital skills training for cancer health care workforce in Europe to support the development of more effective, person-centred health care, digital cancer care services and the use of contemporary eHealth technology.

The EU-CanIneq project aims to develop a research and data framework to create indicators of socioeconomic inequality in cancer, integrate these indicators into the European Cancer Inequalities Registry, analyse data on total cancer mortality and mortality f and produce country-specific information.

Genomics plays an emerging role in clinical health research. CAN.HEAL is using next generation sequencing technology and identifying implementation paths to extend the application of genetic profiling of patients and examining novel insights for estimating cancer risks in healthy populations.

CHIP-AML22 implements advanced genetic diagnostics and targeted treatments for children with AML within the consortium. Recent risk-adapted treatment based on cytogenetics and MRD measurements has improved survival rates to 70%.

PCM4EU combines the expertise of partners from 15 European countries to promote personalised cancer medicine (PCM) – an emerging approach that offers patients more precise and targeted diagnostics and treatment.